Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising Incidence of acromegaly and pituitary tumors
3.2.1.2 Increasing awareness of acromegaly and demand for early diagnosis
3.2.1.3 Expanding research and development activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects of the treatment
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porters anlaysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Ectopic acromegaly
5.3 Pseudo acromegaly
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Medical therapy
6.2.1 Type
6.2.1.1 Somatostatin analogs
6.2.1.2 Growth hormone receptor antagonists (GHRA)
6.2.1.3 Dopamine agonists
6.2.1.4 Combination therapy
6.2.2 Route of administration
6.2.2.1 Oral
6.2.2.2 Injectable
6.2.2.3 Intranasal
6.3 Surgery
6.4 Other treatment types
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Less than 40
7.3 41-60
7.4 61 above
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 ADVANZ PHARMA
9.2 Amryt Pharma Plc
9.3 Chiasma, Inc.
9.4 Cipla
9.5 Crinetics Pharmaceuticals Inc.
9.6 Dauntless Pharmaceuticals
9.7 Eli Lilly and Company
9.8 Ipsen SA
9.9 Novartis AG
9.10 Pfizer Inc.
9.11 Sun Pharmaceutical Industries Ltd.
